DSIP, short for delta sleep-inducing peptide, is a naturally occurring nonapeptide first reported in the 1970s from rabbit brain blood. It is studied in cell culture and animal models as a case of a small neuropeptide whose function and receptor remain unresolved, and as a test case for the handling of acidic, protease-sensitive peptides. Its name records an early observation and is not a settled description of its biology, because later replication was mixed. This article summarises its structure, the state of knowledge about its mechanism, the published research areas and the analytical and storage standards needed for reproducible work. It is written for laboratory researchers and offers no guidance on human use.
What is DSIP?
DSIP is classified as a neuropeptide. Its sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, usually written WAGGDASGE. It has nine residues and a molecular weight of approximately 848 Da for the free peptide, with a molecular formula near C35H48N10O15. The sequence is rich in small residues and carries two acidic amino acids, aspartate and glutamate, with no basic residues, so the peptide has a net negative charge at neutral pH and is highly soluble in water. The single tryptophan at the N-terminus is the only aromatic residue.
The peptide was reported in 1977 by Georges Schoenenberger and Marcel Monnier, working in Basel. In their experiments, blood from the cerebral veins of rabbits in which sleep had been induced by electrical stimulation of the thalamus was dialysed, and the dialysate was reported to alter electroencephalographic activity when infused into recipient rabbits. Fractionation of the dialysate led to the isolation and sequencing of the nonapeptide, and the name reflects the original observation of slow-wave (delta) activity in the recipient animals. A phosphorylated form of the peptide, in which the serine is phosphorylated, was later described and is of interest because phosphorylation may protect the peptide from degradation.
Researchers will also see references to DSIP-like immunoreactivity, which is a term from work using antibodies raised against the peptide. Those antibodies reacted with several proteins and tissues, and later work indicated that the immunoreactivity did not necessarily reflect the presence of the nonapeptide itself. This matters for interpreting older literature.
Regulatory context matters for any UK buyer. To the author’s understanding, DSIP is not authorised as a medicine in the United Kingdom, and this should be checked against current Medicines and Healthcare products Regulatory Agency (MHRA) records. Anti-doping status should be checked against the current World Anti-Doping Agency list. The MHRA has issued warnings about unlicensed products marketed for human use. The material is relevant here only as a laboratory research reagent.
Mechanism of action
The honest summary of the mechanism of DSIP is that it is not known. No receptor has been conclusively identified, and the gene encoding a precursor protein that would release the nonapeptide has not been established in the way it has for classical neuropeptides. This is the most important point to understand about the compound.
Several proposals appear in the literature. The first is a modulatory role in neurotransmitter systems. Studies in rodent brain tissue and in cell preparations reported effects on the release or action of serotonin, GABA and other transmitters, and on the activity of certain ion channels. These reports describe observations in specific preparations and have not been consolidated into a defined receptor mechanism.
The second proposal concerns the hypothalamic-pituitary-adrenal axis. Reports described effects of the peptide on the release of corticotropin-releasing hormone, luteinising hormone and other pituitary hormones in rat preparations. Again, the findings come from a limited number of groups and are not uniformly replicated.
The third relates to stress and metabolic responses, where the peptide has been reported to alter markers in rodents under experimental stress. These findings are descriptive and do not define a molecular target.
A fourth strand concerns the relationship between the peptide and a protein now known as TSC22D3, or glucocorticoid-induced leucine zipper (GILZ). Researchers who identified a protein recognised by anti-DSIP antibodies reported that its sequence was unrelated to a nonapeptide precursor, which complicated the question of where endogenous DSIP originates. The details are specialised and are best read in the primary literature.
For laboratory design, the practical consequence is that results cannot be interpreted as acting through a defined receptor. Controls are essential, including scrambled-sequence peptides, the phosphorylated and unphosphorylated forms, and dose-response series. In cell-based work, “dosage” means molar concentration in the medium, which depends on net peptide content, adsorption to plasticware and, critically, protease activity, because DSIP is cleaved rapidly by aminopeptidases. Reported half-lives in plasma are on the order of minutes, so the effective concentration can fall quickly during an experiment, and stability in the chosen medium should be measured.
What the research shows
The literature on DSIP is moderate in size and notable for its inconsistency. Four areas are summarised below in general terms. Readers should consult the primary papers for methods, concentrations and statistics, because commercial summaries, especially those found on sales pages, often overstate findings.
The first area is the original isolation. The 1977 report from Schoenenberger and Monnier described the cross-circulation and dialysis experiments, the purification of the peptide and its sequence, and the reported effects on electrical activity in recipient rabbits. This is the foundation of the field, and it is a rabbit study from a single laboratory. The work can be located through a PubMed search for the characterisation of delta sleep-inducing peptide by Schoenenberger and Monnier.
The second area is the replication literature. Following the 1977 report, many laboratories attempted to reproduce the reported effects in rats, rabbits, cats and other species, using different routes and exposures. Results were mixed, with some groups reporting effects and others reporting none, and reviews in the 1980s discussed the difficulty of reproducing the findings and the possible influence of experimental conditions. Exposures in these animal studies were expressed per kilogram of body weight and varied widely with species and route, so values should be taken from the primary papers. The review literature can be explored through a PubMed search on DSIP review of effects and replication in animal studies.
The third area is the biochemistry of the peptide. Studies examined its degradation in plasma and brain tissue, identified aminopeptidase cleavage at the N-terminal tryptophan as a main route and described the phosphorylated form and its apparent greater stability. This work is relevant to anyone designing an experiment, because it shows how quickly the intact peptide can be lost.
The fourth area is the question of an endogenous precursor. Molecular biology work in the 1990s and later investigated whether a gene or protein could account for the nonapeptide, and reported that antibodies against DSIP recognised an unrelated protein. This work explains why the endogenous biology of DSIP is regarded as unresolved.
A recurring limitation runs through this body of work. The original findings were difficult to replicate, no receptor has been identified, older studies relied on immunoassays whose specificity was later questioned, and the exact material used in studies is not always characterised analytically. Findings should therefore be treated as provisional, and reproducibility depends heavily on knowing exactly what was in the vial.
Research applications
In the laboratory, DSIP is used in a narrow set of contexts. The most common is as a test compound in neuropeptide pharmacology, where researchers examine its effects on neuronal and glial cell cultures and brain slice preparations, including neurotransmitter release and electrophysiological readouts, with scrambled-sequence and stability controls.
A second context is peptide stability and metabolism research. Because the nonapeptide is cleared quickly by aminopeptidases and has a phosphorylated variant, it is a convenient model for studying how N-terminal protection, phosphorylation and D-amino acid substitution alter half-life. Plasma stability assays use it as a comparator.
A third context is the history and methodology of neuropeptide discovery. The DSIP story, in which an observation in one laboratory led to a named peptide whose biology proved hard to confirm, is used in teaching and in discussions of reproducibility and of the specificity of immunoassays.
A fourth context is animal models, which require institutional ethical review and, in the United Kingdom, authorisation under the Animals (Scientific Procedures) Act 1986. Study design should include vehicle controls, blinded assessment and analytical confirmation of the material administered, given the history of inconsistent results.
A fifth context is analytical chemistry. A small, acidic, tryptophan-containing peptide is a useful test case for liquid chromatography and mass spectrometry methods for polar peptides, and reference material of defined identity and purity supports method development and the detection of unlicensed peptide products.
Purity, storage and handling
DSIP is short, but its chemistry has several points of difficulty. The tryptophan residue is susceptible to oxidation, adding 16 Da per oxidation event, and to modification during cleavage from the resin if scavengers are inadequate. The aspartate-alanine and glycine-aspartate-containing stretches can undergo aspartimide formation during synthesis, giving isomeric impurities that are hard to separate from the target. The glutamate at the C-terminus can cyclise under some conditions. The peptide is highly polar and acidic, so it may elute early on a standard C18 column and may not be well retained, which makes separation of closely related impurities difficult. Reversed-phase high-performance liquid chromatography (HPLC) with UV detection at 214 or 220 nm is the standard purity method, and a main peak of at least 98 per cent is commonly expected. The tryptophan also absorbs near 280 nm, so a second wavelength helps to identify the peptide and to detect impurities lacking the aromatic residue. A shallow gradient or an alternative separation mode may be needed, and a stated purity is meaningful only if the method and chromatogram are available.
HPLC must be paired with mass spectrometry. The expected protonated ion is at about m/z 849. A species 16 Da higher indicates tryptophan oxidation, and a species lacking one residue indicates a deletion product. Aspartimide-derived isomers can share the target mass, which is why retention time and orthogonal methods matter. A clean peak at the wrong mass is a clean peak of the wrong compound, and for the phosphorylated form the mass should show the additional 80 Da.
A batch-specific certificate of analysis matters because purity, peptide content and counterion content vary between synthesis runs. It should carry a lot number matching the vial, the HPLC trace or purity value, the observed and theoretical masses, the test date and ideally the salt form, net peptide content and endotoxin result. The counterion deserves attention for a peptide of only about 848 Da, because a small peptide can carry a large relative amount of counterion and water, so the weighed mass is a poor guide to the amount of peptide, and ignoring this introduces systematic errors into any concentration-response comparison. The certificate should also state whether the peptide is the unphosphorylated nonapeptide or a phosphorylated variant.
Because the peptide is cleared quickly in biological media and the tryptophan oxidises readily, and because the history of the field shows how much conclusions depend on reproducibility, batch-level verification matters more here than with a robust sequence. UK laboratories sourcing DSIP should expect a batch-specific certificate of analysis that states the mass found, the salt form and net peptide content, with lyophilised storage at -20°C, and the same documentation standard applies when weighing any best peptides supplier uk claim, since a supplier’s analytical record rather than its search ranking shows whether the vial matches its stated specification.
Lyophilised DSIP is generally stored at -20°C in a sealed container with desiccant, and many laboratories use -80°C for long-term archives. Vials should reach room temperature before opening so that condensation does not form on the cold powder. After reconstitution, stability falls sharply. Standard practice is to dissolve the peptide in sterile, endotoxin-free water or a suitable buffer immediately before use where possible, divide any stock into single-use aliquots and freeze them to avoid repeated freeze-thaw cycles. Refrigerated storage at 2 to 8°C should be limited, and the acceptable period should be validated for the assay concerned, preferably by re-running HPLC and mass spectrometry on stored solution. Degassed buffers can slow tryptophan oxidation, and neutral to alkaline pH can accelerate aspartate-related degradation.
Light sensitivity is a real concern for this sequence, since the tryptophan residue undergoes photo-oxidation readily, so amber vials or dark storage are advisable and prolonged exposure to bright laboratory lighting should be avoided. Peptides also adsorb to glass and some plastics at low concentrations, so low-bind tubes are preferred for dilute working solutions.
Labelling is a final indicator of quality. Clear naming, sequence, molecular weight, lot number, salt form, whether the peptide is phosphorylated and an unambiguous research-only statement suggest a supplier that understands its market. Any wording that implies use in humans, including any language about sleep, is a warning sign and raises regulatory concerns in the United Kingdom.
Frequently asked questions
What is DSIP used for in laboratory research?
It is used as a test compound in neuropeptide pharmacology in cultured cells and tissue preparations, in studies of peptide stability and metabolism, in teaching examples about reproducibility and in analytical methods. It is a research reagent and not an authorised medicine in the United Kingdom.
What is the sequence and molecular weight of DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, usually written WAGGDASGE, and a molecular weight of about 848 Da. The certificate of analysis should show a mass spectrometry result matching this value and state whether it is phosphorylated.
Is the evidence for DSIP strong?
No. The original 1977 findings came from one laboratory, replication attempts gave mixed results, no receptor has been identified and the endogenous precursor is unresolved. Findings should be treated as provisional, and the peptide is not an authorised medicine in the United Kingdom.
How should DSIP be stored for research?
Keep lyophilised peptide at -20°C, or -80°C for long-term archiving, in a sealed, dry, light-protected container. Allow vials to reach room temperature before opening. After reconstitution, use promptly or aliquot and freeze, because the peptide degrades quickly in solution.
DSIP is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
Research material from Peptides Lab UK: DSIP for laboratory research (UK dispatch, batch certificate of analysis, research use only).
